Market Place
Sourcing Support
Zcube Announces 5 Startups For New Edition Focused Women`s Health
10 Oct 2024 //
PRESS RELEASE
Zambon Ventures Leads C$2 million investment In Health Innovation
24 Sep 2024 //
PRESS RELEASE
Zambon Partners With Kinaxis For Supply Chain Transparency
23 Sep 2024 //
BUSINESSWIRE
Zambon Phase 3 Study Shows Success In CMS I-neb Efficacy In NCFB
13 Sep 2024 //
PRESS RELEASE
Zambon Publishes Phase 3 PROMIS I And II Results In Lancet Respiratory
13 Sep 2024 //
BUSINESSWIRE
Zambon Publishes Phase 3 Results Of CMS I-neb In Bronchiectasis
12 Sep 2024 //
PR NEWSWIRE
Zcube Launches 2024 Open Accelerator For Life Sciences Startups Focusing On Women`s Health
27 Feb 2024 //
PRESS RELEASE
Amneal Enters into European Licensing Agreement with Zambon Biotech for IPX203
27 Feb 2024 //
PRESS RELEASE
Safinamide mesylate by Zambon Co for Multiple System Atrophy Likelihood Approval
28 Aug 2023 //
PHARMACEUTICAL TECHNOLOGY
Zambon Shares Phase 3 PROMIS Studies Results Of CMS I-neb At Bronchiectasis Conference
18 Jul 2023 //
PRESS RELEASE
Zambon Presents Results Showcasing Impact of Bronchiolitis Obliterans Syndrome
23 May 2023 //
PRESS RELEASE
Zambon Announces Data Highlighting Lifetime Burden of Illness in BOS
09 May 2023 //
PRESS RELEASE
Zambon Announces New Data Highlighting Lifetime Burden of Illness U.S. Patients
08 May 2023 //
PR NEWSWIRE
Zambon Completes Enrollment in Phase 3 Development Program Evaluating L-CsA-i
02 May 2023 //
PRESS RELEASE
Zambon Completes Enrollment in Pha3 Clinical DevP Program (L-CsA-i)
01 May 2023 //
PR NEWSWIRE
Zambon and IMA Active: paving the way towards process optimisation
23 Nov 2022 //
PHARMACEUTICAL MANUFACTURER
Zambon to Attend the CHEST Annual Meeting 2022
14 Oct 2022 //
PR NEWSWIRE
Zambon Announces Attendance at ATS 2022 Annual Meeting
12 May 2022 //
PRNEWSWIRE
Zambon Receives U.S. FDA Breakthrough Therapy Designation for CMS I-neb®
21 Apr 2022 //
PRESS RELEASE
Near Angers. Strike at Zach system in Avrillé, the Seveso-classified factory
07 Mar 2022 //
OUEST FRANCE
Positive Results from Ph3 PROMIS-I Study of CMS I-neb® in Non-Cystic Fibrosis
08 Sep 2021 //
BIOSPACE
On the World Parkinson’s Day, Zambon announces Synapses study’s results
12 Apr 2021 //
PRESS RELEASE
Newron & Zambon sign agreement for potentially pivotal study with safinamide
15 Mar 2021 //
PRESS RELEASE
Newron and Zambon Sign Agreement for Potentially Pivotal Study with safinamide
15 Mar 2021 //
BUSINESSWIRE
Newron and Zambon Sign Agreement for Potentially Pivotal Study
15 Mar 2021 //
BUSINESSWIRE
The importance of protecting the lungs from oxidative stress for COPD patients
19 Nov 2020 //
PRESS RELEASE
Zambon entered in an exclusive license agreement to register and commercialize riluzole Oral Film in Europe for ALS
13 Nov 2019 //
PRESS RELEASE
Breath Therapeutics, a Zambon company, announces presentations at upcoming scientific conferences
16 Oct 2019 //
PRESS RELEASE
Zambon’s acquisition creates position to ‘achieve advances’ for res diseases
05 Aug 2019 //
IN-PHARMATECHNOLOGIST
Zambon completes transformational acquisition of Breath Therapeutics
25 Jul 2019 //
PRESS RELEASE
Zambon completes “transformational” acquisition
25 Jul 2019 //
THE PHARMALETTER
Clariant Now Producing Desiccant Packets at India Plant
25 Jul 2019 //
CONTRACT PHARMA
Zambon Acquires Sofinnova Partners’ Breath Therapeutics
25 Jul 2019 //
CONTRACT PHARMA
Valeo Pharma Announces the Canadian Launch of Onstryv® (Safinamide Tablets)
11 Jul 2019 //
PRESS RELEASE
Zambon and Valeo Pharma launch PD drug Onstryv in Canada
11 Jul 2019 //
THE PHARMALETTER
Italy drugmaker Zambon ready to splash out in US, China push
25 Jan 2019 //
REUTERS
Valeo Pharma and Zambon announce the approval of Onstryv® (safinamide)
15 Jan 2019 //
PRESS RELEASE
Zambon for Colistimethate Sodium Powder for Nebulizer Solution
11 Dec 2018 //
BUSINESSWIRE
Zambon announces approval and ARTG listing of Safinamide in Australia
30 Nov 2018 //
PRESS RELEASE
AstraZeneca and Zambon Announce a Strategic Partnership at CIIE
13 Nov 2018 //
PRESS RELEASE
Research Venture of Zambon pharmaceutical group presents the Open Accelerator 2018
12 Jun 2018 //
PRESS RELEASE
Zambon and Seqirus will collaborate to sell new Parkinson`s treatment
01 Nov 2017 //
PHARMALETTER
Xadago® (Safinamide) Now Available In The U.S. For Parkinson’S Disease Patients
31 Jul 2017 //
PRESS RELEASE
Release of New FDA Guidance Declines Sharply Following Trump’s Inauguration
12 Apr 2017 //
RAPS
Valeo Pharma and Zambon form partnership for Parkinson’s Disease
11 Apr 2017 //
PRESS RELEASE
Zambon Launches Xadago® In Portugal For Patients With Mid- To Late-Stage
10 Apr 2017 //
PRESS RELEASE
Fda Approves Xadago® (Safinamide) For Parkinson’S Disease (Pd) Patients
21 Mar 2017 //
PRESS RELEASE
Newron Hopes to Partner would-be Schizophrenia Blockbuster this Year
27 Jan 2017 //
FIERCE BIOTECH
Seqirus and Zambon enter into a partnership for Parkinson’s disease product
10 Jan 2017 //
PRESS RELEASE
Agreement Zambon -(FIS) for the development of the Lonigo plant
02 Nov 2016 //
PRESS RELEASE
